[1] Lun LG. Pathogenesis of hepatic encephalopathy[J]. Chin J Hepatol,2004, 12(5):304-6. [2] 姜忠妹,裴的善.肝性脑病药物的去氨作用[J].中国药学(Chin Pharm),2004,13(7):78-9. [3] 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志(Chin JInfectDis),2001,19(1):56-62. [4] MarkB,TaylorM.潘国宗译.胃肠急症学[M].北京:中国协和医科大学出版社,1998.321-38. [5] 姜树椿.传染病基础与临床[M].北京:军事科学出版社,1999.384-6. [6] 蒋树林,姚希贤.幽门螺杆菌粘膜致病机理研究现状[J].胃肠病学和肝病学杂志(J Gastroenterol Heper),1997,6(2):100-3. [7] 王卫卫,杨希山,吴平生,等.纤维化及正常肝组织中血管紧张素Ⅱ1型受体mRNA的表达[J].第一军医大学学报,2003,23(5):477-9Wang WW, Yang XS, Wu PS, et al. Expressions of angiotensin Ⅱtype 1 receptor mRNA in fibrotic and normal liver tissues[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2003, 23(5):477-9. [8] 朱宁川,陈岩.肝病肠道菌群失调与肠源性内毒素血症[J].中国微生态学杂志(Chin J Microeco1),2004,16(1):61-2 [9] 刘厚鈺,石虹.门体性肝性脑病的治疗进展[J].中华消化杂志(Chin J Dig),1999,19(3):191-3. [10] Ferenci P, Herneth A, Steindl P. Newer approaches to therapy of hepatic encephalopathy [J]. Seminliver Dis, 1996, 16(2):329-36. [11] Kircheis G, Niling R, Held C, et al. The therapeutic efficacy of Lornithine-L-as partate infusions in patients with cirrhosis and hepatic encephalopathy:Results of splacebo-controlled,double-blind study[J]. Hepatology, 1997, 25(12):1351-60. [12] Rees CJ, Oprpong K, AlMardini H, et al. Effect of L-ornithine-Laspartate on patients with and without TIPS undergoing glutamine challenge:a double blind, placebo controlled trial[J]. Gut, 2000, 47(4):571-4. |